Features Partner Sites Information LinkXpress
Sign In
Demo Company

New Microplate Reader Optimized for Fluorescent and Bioluminescent Assays

By BiotechDaily International staff writers
Posted on 13 Feb 2014
Print article
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Biotech and other life science researchers now have available a new microplate reader system that provides superior sensitivity, performance, and flexibility with minimal user intervention.

Promega Corporation (Madison, WI, USA) has launched the GloMax Discover, an integrated multimode detection plate-reader system. This system was designed to enable investigators to easily study cell signaling and metabolism, while monitoring cell viability, apoptosis, and cytotoxicity, or to study gene expression with a wide variety of reporter assays.

The instrument offers a broad dynamic range for both strong and weak bioluminescence experimental samples, superior luminescence sensitivity, and low well-to-well cross talk, which enables users to generate more usable data from each experiment. The GloMax Discover provides flexible use of filters for fluorescence intensity, BRET (bioluminescence resonance energy transfer), FRET (fluorescence resonance energy transfer), filtered luminescence, and UV-visible absorbance measurements. In addition, the system encourages seamless integration with industry-leading bioluminescent assays.

The GloMax Discover is driven by proprietary software that provides quick and easy navigation through the control options, preloaded assay protocols, and drag-and-drop protocol customization.

Michael Bjerke, global product manager, detection at Promega, said, “Scientific discoveries not only require the right type of assay to achieve the necessary sensitivity, dynamic range, and reproducibility, they require the right type of instrument. Instruments with enhanced optical capability, such as our GloMax systems with high quality luminescence, enable superior assay performance and experimental design.”

Related Links:

Promega Corporation

Print article



view channel
Image: Cryoelectron micrograph reconstruction of the Chikungunya virus (Photo courtesy of the Washington University School of Medicine).

Broadly Neutralizing Antibodies Protect Mice from Alphavirus Infection

While screening a panel of mouse and human monoclonal antibodies (MAbs) that had been raised against Chikungunya virus, researchers identified several with inhibitory activity against multiple other arthritogenic... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.